左起依次为：英矽智能联席首席执行官、首席科学官任峰博士，药明康德高级副总裁、合全药业原料药业务部负责人傅小勇博士
中国上海，2022年9月1日 -- 药明康德子公司合全药业与端到端人工智能驱动的药物研发公司英矽智能（Insilico Medicine）共同宣布，针对一体化CMC服务签署战略合作协议。英矽智能联席首席执行官、首席科学官任峰博士，药明康德高级副总裁、合全药业原料药业务部负责人傅小勇博士，合全药业高级副总裁、制剂业务负责人陈金玲博士等共同出席了签约仪式。
英矽智能是一家由端到端人工智能（AI）驱动的药物研发公司，管线覆盖癌症、纤维化、免疫、中枢神经系统疾病以及衰老相关疾病等领域，已开发超30条自研管线。其中进展最快的抗纤维化项目ISM001-055目前正在新西兰和中国同步开展1期临床试验。公司于2021年与合全药业展开合作，合全药业为其抗纤维化项目提供了原料药及制剂的研发和生产端到端支持。
合全药业作为CRDMO领军企业，2017年以来已成功支持合作伙伴的35款创新药获批，支持的新药在全球105个国家上市。此次英矽智能与合全药业签署战略合作协议，是在ISM001-055成功合作的基础上，进一步拓展双方合作的深度和宽度。根据战略合作协议，合全药业将成为英矽智能在新药合同研究、开发与生产领域（CRDMO）的首选合作伙伴，为其在研及后续管线产品提供原料药及制剂产品的研究、工艺开发、生产、分析以及支持新药申报的注册文件准备等一站式服务。
“我们非常高兴借助合全药业端到端CMC平台加快项目进度，双方过去的合作卓有成效。”英矽智能创始人兼首席执行官Alex Zhavoronkov博士表示：”相信此次深化合作，将帮助我们进一步提升药物开发的速度和效率，早日满足迫切的临床医疗需求。”
“很高兴与英矽智能强化合作关系。”药明康德联席首席执行官、合全药业首席执行官陈民章博士表示：“合全药业将继续提升一体化CRDMO平台能力，更好地赋能合作伙伴加速创新药开发，惠及全球病患。”
关于合全药业
合全药业是药明康德子公司，在亚洲、北美及欧洲地区均设有研发及生产基地。合全药业服务于生命科学行业，拥有卓越的化学创新药研发和生产的能力和技术平台。作为全球新药合同研究、开发与生产领域（CRDMO）的领军企业，合全药业致力于为全球合作伙伴提供高效、灵活、高质量的一站式解决方案，以支持包括小分子、寡核苷酸、多肽及各种复杂化学偶联药物的研发与生产。更多信息，请访问公司网站：www.stapharma.com.cn
WuXi STA Forms Strategic Partnership with Insilico Medicine
From left to right: Insilico Medicine co-CEO and Chief Scientific Officer Dr. Feng Ren, WuXi AppTec Senior Vice President and WuXi STA API Business Head Dr. Xiaoyong Fu
SHANGHAI, CHINA, September 1, 2022 – WuXi STA, a subsidiary of WuXi AppTec, and Insilico Medicine, a global clinical-stage artificial intelligence-driven drug discovery and development company, today announced a strategic partnership for the integrated CMC services.
Insilico Medicine owned more than 30 pipelines under development, covering various diseases, including cancers, fibrosis, immunity, central nervous system diseases, and aging-associated diseases. Insilico’s leading anti-fibrosis drug candidate, ISM001-055, is undergoing phase 1 clinical trials in both New Zealand and China. The collaboration between WuXi STA and Insilico started in 2021, while WuXi STA provided the end-to-end CMC service, including both API and formulation development and manufacturing for ISM001-055.
As the leading CRDMO, WuXi STA has supported 35 new drugs approved globally since 2017, and the products manufactured have been launched in 105 countries. This strategic partnership is to broaden the collaboration between WuXi STA and Insilico beyond ISM001-055. Under this agreement, WuXi STA will be the preferred contract research, development, and manufacturing organization (CRDMO) partner and will provide integrated end-to-end CMC solutions to Insilico’s current and future drug discovery and development projects. The services include but are not limited to API and drug product research, development, manufacturing, and regulatory CMC dossier preparation services.
Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine, commented:“We are excited to have WuXi STA’s end-to-end CMC platform supporting our projects. The past collaboration was fruitful, and I believe this collaboration expansion will greatly accelerate our pipelines to the market and fulfill the patients’ demand around the world.”
Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, commented:“We are pleased to enhance our partnership with Insilico. We will continue building our integrated CRDMO platform and look forward to empowering more breakthroughs to benefit patients worldwide.”
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.
For more information, please visit: http://www.STApharma.com
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.
For more information, visit www.insilico.com
